Siltuximab
Based on 4 publication(s) in Google Scholar
Siltuximab is an anti-IL-6 (interleukin-6) monoclonal antibody, and shows antitumor activity. Siltuximab can be used in Multicentric Castleman's Disease (MCD) and COVID-19 research.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: ≥99.0%
- CAS. Nr.: 541502-14-1
- Molecular Weight:144.98 kDa
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Siltuximab
More
Customer Validation & Images
-
Cell Imaging/Staining
-
IF
Biologische Aktivität
Human IgG1 kappa
Human
IL-6/IFNb2
Siltuximab (intraperitoneal injection; 20 mg/kg; twice per week; 6 w) inhibits the growth of MCF-7 tumor in xenograft model[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female CD-1 nu/nu mice injected with H1650 (adenocarcinoma), H322 (adenocarcinoma), or H157 (squamous) cells[3]
-
Dosage:10 mg/kg
-
Administration:Intraperitoneal injection; 10 mg/kg; 3 times per week
-
Result:Repressed PY-STAT3 levels stimulated by IL-6 in H322 cells.
Repressed PY-STAT3 levels in H1650 cells.
Inhibited the growth of tumors with H322 and CAF cells.
Inhibited the growth of tumors with H1650 and CAF cells.
-
Animal Model:Female NOD-SCID mice with MCF-7 tumor[4]
-
Dosage:20 mg/kg
-
Administration:Intraperitoneal injection; 20 mg/kg; twice per week; 6 weeks
-
Result:Blocked MCF-7 engraftment, induced regressions in 90% of tumors.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Immobilized IL-6 Protein, Human (HY-P7044) can bind Siltuximab. The EC50 for this effect is 4.04 ng/mL. -
Flow cytometric analysis of 1.5×106 Siha cells with Siltuximab (HY-P9956, red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa Isotype Control (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
CAS. Nr. 541502-14-1
-
Appearance Liquid
-
Molecular Weight 144.98 kDa
-
Color Colorless to light yellow
-
SMILES
[Siltuximab]
-
Synonyms
CNTO-328
-
Versand
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
ACS Nano
Combining Microfluidic Assessment with Encoded Hydrogel Microparticle-Based Immunoassay for Anti-Interleukin Drug Repurposing of Pulmonary Fibrosis Therapy. [Abstract]2025 Sep 16;19(36):32361-32373. PMID: 40903905
Siltuximab purchased from MedChemExpress. Usage Cited in: ACS Nano. 2025 Sep 16;19(36):32361-32373. [Abstract]
Representative images of fibrosis-induced spheroids subjected to microfluidic deformation analysis, comparing untreated control, antifibrotic drug NTD, and anti-interleukin drugs TCZ, STX, DUP, and TRA. Mab (5 μg/mL, 1 d) were added, Scale bars indicate 100 μm.
Siltuximab purchased from MedChemExpress. Usage Cited in: ACS Nano. 2025 Sep 16;19(36):32361-32373. [Abstract]
Confocal fluorescence images showing the expression of collagen-1 and α-SMA in spheroids treated with NTD, TCZ, STX, DUP, and TRA. Mab (5 μg/mL, 1 d) were added, Scale bars indicate 100 μm.
-
J Transl Med
Esophageal microbial dysbiosis impairs mucosal barrier integrity via toll-like receptor 2 pathway in patients with gastroesophageal reflux symptoms. [Abstract]2024 Dec 24;22(1):1145. PMID: 39719586 -
Brain Behav Immun
A gut-adipose-nerve axis mediates inulin protection against Western diet-induced somatosensory dysfunction. [Abstract]2026 May 4:137:106795. PMID: 42092466 -
Esophagus
Acid bile salt induces esophageal mucosal barrier dysfunction through miR-146a-5p-KYNU pathway in gastroesophageal reflux disease. [Abstract]2026 Apr;23(2):419-433. PMID: 41703371
Reinheit & Dokumentation
-
Data Sheet (262 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Verweise
[1]. Karkera J, et al. The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study. Prostate. 2011 Sep 15;71(13):1455-65. [Content Brief]
[2]. Khan FA, et al. Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19. Thorax. 2021 Sep;76(9):907-919. doi: 10.1136/thoraxjnl-2020-215266. Epub 2021 Feb 12. [Content Brief]
[3]. Song L, et al. Antitumor efficacy of the anti-interleukin-6 (IL-6) antibody siltuximab in mouse xenograft models of lung cancer. J Thorac Oncol. 2014 Jul;9(7):974-982. [Content Brief]
[4]. Casneuf T, et al. Interleukin-6 is a potential therapeutic target in interleukin-6 dependent, estrogen receptor-α-positive breast cancer. Breast Cancer (Dove Med Press). 2016 Feb 3;8:13-27. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Siltuximab Related Classifications
HY-P9956 Related Classifications
Powered by Bioz